Dr. Woodard will implant the biodegradable device, which is designed to stabilize spinal cord injuries within six weeks and then dissolve, in the spinal cords of five patients.
InVivo’s small scale study is the first human trial of a spinal cord treatment device.
InVivo is a Cambridge, Mass.-based medical device company focused on the treatment of spinal cord injuries.
Dr. Woodard also currently serves as the chief of neurosurgery at New England Baptist Hospital in Boston.
More Articles on Spine:
Dr. Jeffery Carlson Performs Procedure With SpineFrontier’s FacetFuse Screw System
Alaska Native Medical Center Names Dr. Roland Torres Clinical Director
7 Things for Spine Surgeons to Know for Thursday
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
